The exon 1-8C/G SNP in the PSMA6 gene contributes only a small amount to the burden of myocardial infarction in 6946 cases and 2720 controls from a United Kingdom population

European Journal of Human Genetics

Volumn 16, Issue 4, 2008, Pages 480-486

  Bennett, Derrick A ^a   Xu, Peng ^b   Clarke, Robert ^a   Zondervan, Krina ^c   Parish, Sarah ^a   Palmer, Alison ^a   Cardon, Lon ^c   Peto, Richard ^a   Lathrop, Mark ^b   Collins, Rory ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEASOME SUBUNIT ALPHA TYPE 6; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CONTROLLED STUDY; DOMINANT GENE; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HOMOZYGOSITY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POPULATION GENETICS; PRIORITY JOURNAL; RECESSIVE GENE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

ADULT; BLOOD PROTEINS; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GREAT BRITAIN; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; MYOCARDIAL INFARCTION; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEASOME ENDOPEPTIDASE COMPLEX; RISK FACTORS;

EID: 41049091365     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201948     Document Type: Article

References (40)

1. Herrmann J, Ciethanover A, Lerman LO, Lerman A: The ubiquitin-proteasome- system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res 2004; 61: 11-21.
2. Palombella VJ, Rando OJ, Goldberg A, Maniatis T: The ubiquitin- proteasome pathway is required for processing the NF-[kappa]B1 precursor protein and the activation of NF-[kappa]B. Cell 1994; 78: 773-795.
3. Meiners S, Laule M, Rother W et al: Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 2002; 105: 483-489.
4. Elliott PJ, ZollnAr TM, Boehncke WH: Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003; 81: 235-245.
5. Ozaki K, Sato H, Iida A et al: A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. Nat Genet 2006; 38: 921-925.
6. Keavney B, McKenzie C, Parish S et al: Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 2000; 355: 434-442.
7. Keavney B, Palmer A, Parish S et al: Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: Discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol 2004; 33: 1002-1013.
8. Clarke R, Xu P, Bennett D et al: Lymphotoxin-alpha gene and risk of myocardial infarction in 6928 cases and 2712 controls in the ISIS case-control study. PLoS Genet 2006; 2: E107.
9. MRC/BHF Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J 1999; 20: 725-741.
10. Clark S, Youngman LD, Palmer A, Parish S, Peto R, Collins R: Stability of Plasma and analyser after delayed separation of whole blood: implications for epidemiological studies. Int J Epidemiol 2003; 32: 125-130.
11. GUO SW, Thompson EA: Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992; 48: 361-372.
12. Lewontin RC: On measures Of gametic disequilibrium. Genetics 1988; 120: 849-852.
13. Hill W, Robertson A: Linkage disequilibrium in finite populations. Theor Appl Genet 1968; 38: 226-231.
14. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phasos ambiguous. Am J Hum Genet 2002; 70: 425-434.
15. Schald DJ: Evaluating associations of haplotypes with traits. Genet Epidemiol 2004; 27: 348-364.
16. Easton DF, Peto J,ABabiker AG: Floating absolute risk: an alternative to relative risk in survival and case-control analysis avioding an arbritrary reference group. Stat Med 1991; 10: 1025-1035.
17. Plummer M: Improved estimates of floating absolute risk. Stat Med 2004; 23: 93-104.
18. Slager SL, Schaid DJ: Case-control Ptudies of genetic markers: power and sample size approximations for Armitage's test for trend. Hum Hered 2001; 52: 149-153.
19. Freidlin B, Zheng G, Li Z, Gastwirth JL: Trend tests for case-control studies of genetic markers: Power, sample size and robustness. Hum Hered 2002; 53: 146-152.
20. Schlesselman JJ: Case-Control Studies: Design, Conduct, Analysis. London: Oxford University Press, 1982.
21. Rockhill B, Newman B, Weinberg C: Use and misuse of population attributable fractions. Am J Public Health 1998; 88: 15-19.
22. SAS.Institutee: SAS Version 8. Cary, North Carolina: SAS Institute, 1999.
23. Ihaka R, Gentleman R: R: a language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299-314.
24. Takashima N, Shioji K, Kokubo Y et al: Validation of the association between the gene encoding proteasome subunit alpha type 6 and myocardial infarction in a Japanese population. Circ J 2007; 71: 495-498.
25. Sjakste T, Poudziunas I, Ninio E et al: SNPs of PSMA6 gene - investigation of possible association with myocardial infarction and type 2 diabetes mellitus. Genetika 2007; 43: 553-559.
26. Morgan TM, Krumholz HM, Lifton RP, Spertus JA: Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007; 297: 1551-1561.
27. Helgason A, Yngvadottir B, Hrafnkelsson B, Gulcher J, Stefansson K: An Icelandic example of the impact of population structure on association studies. Nat Genet 2005; 37: 90-95.
28. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P: Association mapping in structured populations. Am J Hum Genet 2000; 67: 170-181.
29. Agrawal A, Cha-Molstad H, Samols D, Kushner I: Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology 2003; 108: 539-547.
30. Wang CH, Li SH, Weisel RD et al: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-1790.
31. Hattori Y, Matsumura M, Kasai K: Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003; 58: 186-195.
32. Cirillo P, Golino P, Calabro P et al: C-reactive protein induces tissue factor expression and promotes Smooth muscle and endothelial cell proliferation. Cardiovasc Res 2005; 68: 47-55.
33. Danesh J, Wheeler JG, Hirschfield GM et al: C-reactive protein and other circulating markers of inflamalation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
34. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrand P: N-terminal pro-brain natriuretic peptide, C- reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.
35. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC: The value of C-reactive protein in cardiovascular risk prediction: The Rotterdam Study. Arch Intern Med 2003; 163: 1323-1328.
36. Guo M, Sahni SK, Sahni A, Francis CW: Fibrinogen regulates the expression of inflammatory chemokines through NF-kappaB activation of endothelial cells. Thromb Haemost 2004; 92: 858-866.
37. Danesh J, Lewington S, Thompson SG et al: Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality: An individual participant meta-analysis. JAMA 2005; 294: 1799-1809.
38. Keavney B, Danesh J, Parish S et al: Fibrinogen and coronary heart disease: Test of causality by 'Mendelian randomization'. Int J Epidemiol 2006; 35: 935-943.
39. Ozaki K, Ohnishi Y. Iida A et al: Functional SNPs -in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-654.
40. ISIS-3 (Third International Study of Infarct Survival) Collborative GrAup: ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.